<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03804515</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-POZ-102</org_study_id>
    <nct_id>NCT03804515</nct_id>
  </id_info>
  <brief_title>A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib</brief_title>
  <official_title>A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine routes of excretion and single-dose PK parameters&#xD;
      for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2&#xD;
      overexpression/amplification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, single-dose study of 14C-labeled poziotinib to determine&#xD;
      routes of excretion and single-dose PK parameters for poziotinib in patients with solid&#xD;
      tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification.&#xD;
&#xD;
      On Day 1, enrolled patients will be admitted to the inpatient unit and all predose&#xD;
      assessments will be completed. Patients will be admitted to the inpatient unit for 9 days. On&#xD;
      Day 2, a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110&#xD;
      μCi) will be administered orally in the morning right after breakfast with at least 200 mL of&#xD;
      water.&#xD;
&#xD;
      Over the following 168 hours, urine and feces will be collected and pooled at specified&#xD;
      intervals for measurement of total radioactivity recovered and subsequent determination of&#xD;
      the routes of elimination of poziotinib and its metabolites. Blood samples will be taken at&#xD;
      specified time points for 168 hours after dosing for estimation of single-dose poziotinib PK&#xD;
      parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID&#xD;
  </why_stopped>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">June 17, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum recovery of the radioactive dose in plasma, urine and feces</measure>
    <time_frame>1 year</time_frame>
    <description>The route of excretion of radioactive poziotinib and its metabolites following single oral administration of 14C-labeled poziotinib in patients with solid tumors suitable for treatment with poziotinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The concentration of 14C-labeled poziotinib and its metabolites in plasma, urine and feces</measure>
    <time_frame>1 year</time_frame>
    <description>To identify major metabolites of poziotinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>14C-labeled Poziotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-labeled poziotinib</intervention_name>
    <description>a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally</description>
    <arm_group_label>14C-labeled Poziotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient can be male or female and is at least 18 years of age&#xD;
&#xD;
          -  Patient must be willing and capable of giving written Informed Consent and willing to&#xD;
             stay in the research unit for 9 days.&#xD;
&#xD;
          -  Patient has a life expectancy of at least 6 months.&#xD;
&#xD;
          -  Histological confirmation of solid tumor cancer that is suitable for poziotinib&#xD;
             therapy. These may include patients with any solid malignancy with either EGFR or HER&#xD;
             2 mutations or EGFR/HER2 overexpression/amplification. Brain metastases are allowed,&#xD;
             if patient is clinically stable and does not require treatment with anticonvulsants or&#xD;
             escalating steroid doses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a diagnosis of primary and or metastatic hepatic or renal carcinomas.&#xD;
&#xD;
          -  Patient is unable to take oral medication or has ongoing Grade ≥2 diarrhea due to any&#xD;
             etiology including Crohn's disease and/or ulcerative colitis.&#xD;
&#xD;
          -  Previous poziotinib exposure&#xD;
&#xD;
          -  Patient has previously participated in a study utilizing 14C.&#xD;
&#xD;
          -  Patient has any pathology or history of procedures expected to change absorption&#xD;
&#xD;
          -  Patient has a PEG (Percutaneous Endoscopic Gastrostomy) tube&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>HER2 mutations</keyword>
  <keyword>EGFR/HER2 overexpression/amplification</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

